Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 8/20 | 0.70 |
| ▸ | CDK1 | P06493 | 4/20 | 0.62 |
| ▸ | CDK2 | P24941 | 4/20 | 0.62 |
| ▸ | MTOR | P42345 | 3/20 | 0.62 |
| ▸ | JAK2 | O60674 | 3/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.51 |
| ▸ | JUN | P05412 | 4/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632085 | 0.90 | SMG1 (0.62) | SMG1CDK1CDK2MTORJAK2 | |
| SCHEMBL12724192 | 0.89 | SMG1 (0.54) | SMG1CDK1CDK2MTORJAK2 | |
| SCHEMBL1633868 | 0.88 | MAPK10 (0.57) | SMG1CDK1CDK2MTORJAK2 | |
| SCHEMBL1633189 | 0.85 | SMG1 (0.50) | SMG1CDK1CDK2MTORJAK2 | |
| SCHEMBL1633017 | 0.84 | SMG1 (0.72) | SMG1CDK1CDK2MTORJAK2 | |
| SCHEMBL1632522 | 0.81 | DKK1 (0.51) | CDK1CDK2MAPK10MAPK8CA12 | |
| SCHEMBL1631949 | 0.80 | DKK1 (0.50) | CDK1CDK2MAPK10CA12CA1 | |
| SCHEMBL1634316 | 0.80 | TBK1 (0.57) | SMG1JAK2JAK3MAPK10JUN | |
| SCHEMBL1634505 | 0.79 | TBK1 (0.55) | SMG1CDK1JAK2JAK3MAPK10 | |
| SCHEMBL1633314 | 0.79 | MAPK10 (0.49) | SMG1CDK1CDK2MTORJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SMG1 1001/4885CDK1 83/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.